Media Summary: Dr. Emily Morris, mathematical statistician at The U.S. Food and Drug Administration will announce two major steps as part of an initiative to

Fda Grand Rounds Advancing Real - Detailed Analysis & Overview

Dr. Emily Morris, mathematical statistician at The U.S. Food and Drug Administration will announce two major steps as part of an initiative to

Photo Gallery

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making
FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease
CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products
CBER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products
FDA Grand Rounds - Adopting Large Language Models for Regulatory Review
FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products
CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products
Advancing Real-Time Clinical Trials
FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces
FDA Grand Rounds - Clinical Omics Biomarker Discovery and Validation in Precision Medicine
CDER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products
FDA Direct: The Power of Real-Time Clinical Trials
View Detailed Profile
FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

Dr. Marie Bradley, Senior Advisor for

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

Dr. Emily Morris, mathematical statistician at

CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

Learn directly from the

CBER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

CBER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

Learn directly from the

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

Dr. Joshua Xu from

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

Dr. David Skelton from

CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

Learn directly from the

Advancing Real-Time Clinical Trials

Advancing Real-Time Clinical Trials

The U.S. Food and Drug Administration will announce two major steps as part of an initiative to

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

Dr. Jayaleka Amarasinghe from

FDA Grand Rounds - Clinical Omics Biomarker Discovery and Validation in Precision Medicine

FDA Grand Rounds - Clinical Omics Biomarker Discovery and Validation in Precision Medicine

Join us for an insightful

CDER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

CDER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

Learn directly from the

FDA Direct: The Power of Real-Time Clinical Trials

FDA Direct: The Power of Real-Time Clinical Trials

Commissioner Makary joins

FDA Grand Rounds on Synthetic Data

FDA Grand Rounds on Synthetic Data

A recording of the